Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New ...
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...
This innovative approach works by NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...
Tiziana and Renaissance will partner to accelerate clinical development and potential commercial launch of nasal foralumab.
Tiziana Life Sciences (TLSA) announced that a nasal anti-CD3 preclinical study is nearing completion, and that foralumab could offer a novel ...
Tiziana Life Sciences, Ltd. has entered into a product development services agreement with Renaissance Lakewood LLC to enhance and scale up the formulation of its lead candidate, intranasal ...
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback